NEW YORK (GenomeWeb News) – Credit Suisse on Monday initiated coverage of Genomic Health with an Outperform rating, Myriad Genetics with a Neutral rating, and Sequenom with an Underperform rating.

Analyst Vamil Divan initiated coverage of Genomic Health with a $43 price target and in a research note highlighted the firm's portfolio of Oncotype tests. He called Oncotype Dx Breast "a best-in-class asset that is likely to gain traction in other forms of breast cancer," and added that Oncotype Dx Colon is gaining positive reaction, driving uptake of the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.